S&P 500   4,998.76 (-0.25%)
DOW   37,959.42 (+0.49%)
QQQ   419.58 (-0.90%)
AAPL   165.44 (-0.96%)
MSFT   400.77 (-0.87%)
META   487.66 (-2.82%)
GOOGL   154.77 (-0.79%)
AMZN   176.19 (-1.69%)
TSLA   149.89 (-0.03%)
NVDA   819.22 (-3.25%)
AMD   151.03 (-2.61%)
NIO   3.88 (-3.00%)
BABA   68.75 (-0.19%)
T   16.38 (+0.31%)
F   12.13 (+0.58%)
MU   109.50 (-2.17%)
GE   151.20 (-1.14%)
CGC   7.76 (-0.89%)
DIS   112.11 (-0.28%)
AMC   3.22 (+10.27%)
PFE   25.59 (+0.79%)
PYPL   62.18 (+0.13%)
XOM   120.71 (+1.85%)
S&P 500   4,998.76 (-0.25%)
DOW   37,959.42 (+0.49%)
QQQ   419.58 (-0.90%)
AAPL   165.44 (-0.96%)
MSFT   400.77 (-0.87%)
META   487.66 (-2.82%)
GOOGL   154.77 (-0.79%)
AMZN   176.19 (-1.69%)
TSLA   149.89 (-0.03%)
NVDA   819.22 (-3.25%)
AMD   151.03 (-2.61%)
NIO   3.88 (-3.00%)
BABA   68.75 (-0.19%)
T   16.38 (+0.31%)
F   12.13 (+0.58%)
MU   109.50 (-2.17%)
GE   151.20 (-1.14%)
CGC   7.76 (-0.89%)
DIS   112.11 (-0.28%)
AMC   3.22 (+10.27%)
PFE   25.59 (+0.79%)
PYPL   62.18 (+0.13%)
XOM   120.71 (+1.85%)
S&P 500   4,998.76 (-0.25%)
DOW   37,959.42 (+0.49%)
QQQ   419.58 (-0.90%)
AAPL   165.44 (-0.96%)
MSFT   400.77 (-0.87%)
META   487.66 (-2.82%)
GOOGL   154.77 (-0.79%)
AMZN   176.19 (-1.69%)
TSLA   149.89 (-0.03%)
NVDA   819.22 (-3.25%)
AMD   151.03 (-2.61%)
NIO   3.88 (-3.00%)
BABA   68.75 (-0.19%)
T   16.38 (+0.31%)
F   12.13 (+0.58%)
MU   109.50 (-2.17%)
GE   151.20 (-1.14%)
CGC   7.76 (-0.89%)
DIS   112.11 (-0.28%)
AMC   3.22 (+10.27%)
PFE   25.59 (+0.79%)
PYPL   62.18 (+0.13%)
XOM   120.71 (+1.85%)
S&P 500   4,998.76 (-0.25%)
DOW   37,959.42 (+0.49%)
QQQ   419.58 (-0.90%)
AAPL   165.44 (-0.96%)
MSFT   400.77 (-0.87%)
META   487.66 (-2.82%)
GOOGL   154.77 (-0.79%)
AMZN   176.19 (-1.69%)
TSLA   149.89 (-0.03%)
NVDA   819.22 (-3.25%)
AMD   151.03 (-2.61%)
NIO   3.88 (-3.00%)
BABA   68.75 (-0.19%)
T   16.38 (+0.31%)
F   12.13 (+0.58%)
MU   109.50 (-2.17%)
GE   151.20 (-1.14%)
CGC   7.76 (-0.89%)
DIS   112.11 (-0.28%)
AMC   3.22 (+10.27%)
PFE   25.59 (+0.79%)
PYPL   62.18 (+0.13%)
XOM   120.71 (+1.85%)
Free Trial
LON:RENE

ReNeuron Group (RENE) Share Price, News & Analysis

→ The “Perfect Storm” for Gold (From Gold Safe Exchange) (Ad)
Free RENE Stock Alerts
GBX 3.38
-0.08 (-2.17%)
(As of 02/5/2024)
Compare
Today's Range
3.28
▼
3.50
50-Day Range
3.38
▼
3.45
52-Week Range
3.28
▼
11.50
Volume
177,373 shs
Average Volume
578,249 shs
Market Capitalization
£1.93 million
P/E Ratio
N/A
Dividend Yield
0.76%
Price Target
N/A
Stock AnalysisChartHeadlinesInsider Trades
RENE stock logo

About ReNeuron Group Stock (LON:RENE)

ReNeuron Group plc researches, develops, and commercializes cell-based therapies in the United Kingdom. The company engages in the development of CTX stem cell therapy candidate for treating stroke disability; and human retinal progenitor cell therapy that is in Phase 2 clinical trial for treating retinitis pigmentosa, a blindness-causing disease. It also develops CTX-derived exosomes that are in the pre-clinical stage, which are Nano-sized vesicles secreted by stem cells. In addition, the company licenses ReNcell products. It has a collaboration agreement with University College London to conduct research into the generation of immune cells from induced pluripotent stem cells for anti-cancer cell therapies. The company was founded in 1997 and is headquartered in Pencoed, the United Kingdom.

RENE Stock Price History

RENE Stock News Headlines

April 19, 2024 | americanbankingnews.com
ReNeuron Group (LON:RENE) Share Price Passes Above 50 Day Moving Average of $3.38
April 17, 2024 | lse.co.uk
ReNeuron CFO steps down to pursue other opportunities
April 19, 2024 | Paradigm Press (Ad)
Forget Bitcoin. Crypto Millionaire Predicts 8,788% Gains For THIS
You might have seen that Bitcoin was one of the best performing assets of 2023. It gained 164%. But a crypto millionaire who has been tracking the space for more than a decade has ABANDONED Bitcoin. He found something better.
April 11, 2024 | americanbankingnews.com
ReNeuron Group (LON:RENE) Shares Pass Above 50-Day Moving Average of $3.40
April 2, 2024 | msn.com
Medtech firm IQ Endoscopes plans to create 100 new jobs and raise millions
March 28, 2024 | lse.co.uk
Upland Resources shares soar as company prepares for Sarawak drilling
March 22, 2024 | msn.com
Company given millions of public money in Welsh Gov's disastrous foray into biotech investments collapses into administration
March 20, 2024 | lse.co.uk
TRADING UPDATES: ReNeuron appoints administrators as rescue talks fail
April 19, 2024 | Paradigm Press (Ad)
Forget Bitcoin. Crypto Millionaire Predicts 8,788% Gains For THIS
You might have seen that Bitcoin was one of the best performing assets of 2023. It gained 164%. But a crypto millionaire who has been tracking the space for more than a decade has ABANDONED Bitcoin. He found something better.
February 21, 2024 | morningstar.com
ReNeuron Group PLC RENE
February 19, 2024 | lse.co.uk
Trident Royalties secures USD40 million revolving credit facility
February 5, 2024 | lse.co.uk
TRADING UPDATES: ReNeuron warns; Gama Aviation pledges cash return
February 5, 2024 | msn.com
Reneuron issues administration warning as biotech firm puts jobs at risk
November 8, 2023 | lse.co.uk
ReNeuron interim loss narrows on lower costs; eyes partnerships
September 18, 2023 | finance.yahoo.com
ReNeuron Group plc (LON:RENE): Is Breakeven Near?
May 19, 2023 | finance.yahoo.com
ReNeuron Group Slides As Insider Purchases Lose Another UK£75k
May 19, 2023 | finance.yahoo.com
ReNeuron Group Slides As Insider Purchases Lose Another UK£75k \
May 16, 2023 | marketwatch.com
2023 Neuronal Cell Culture Media Market Size and Research Report in Medical Devices & Consumables Sector | with [104 Pages] and Forecast till 2031
May 13, 2023 | marketwatch.com
Global Retinitis Pigmentosa Treatment & Management Market Report 2023-2030: Top Growth Opportunities and Trends
April 27, 2023 | marketwatch.com
Critical Limb Ischemia Drug Market Size by 2031
April 20, 2023 | marketwatch.com
Placental Stem Cell Therapy Market [2023-2030]: Detailed Growth Analysis
April 7, 2023 | marketwatch.com
Stem Cell Therapy Market Size, Revenue, and Forecast 2030
March 28, 2023 | uk.finance.yahoo.com
Global Market for Stem Cells 2023: Potential as Disease Treatment Options Fuels Market Momentum
March 21, 2023 | uk.finance.yahoo.com
Global Market for Stem Cells
March 13, 2023 | proactiveinvestors.com
ReNeuron to present at Advanced Therapies 2023 conference
February 13, 2023 | proactiveinvestors.com
ReNeuron Group’s investment potential ‘remains intact’, 2024 cash runway secured, says Liberum
January 19, 2023 | marketwatch.com
ReNeuron Group Cuts 40% of Staff, Cash Extended into 2024
See More Headlines
Receive RENE Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for ReNeuron Group and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings
7/20/2020
Today
4/19/2024
Get Stock Alerts

Industry, Sector and Symbol

Stock Exchange
LON
Sector
Medical
Industry
Biotechnology
Sub-Industry
N/A
Current Symbol
LON:RENE
CUSIP
N/A
CIK
N/A
Web
www.reneuron.com
Phone
+44-20-38198400
Fax
N/A
Employees
26
Year Founded
N/A

Profitability

EPS (Most Recent Fiscal Year)
GBX (0.09)
Trailing P/E Ratio
N/A
Forward P/E Ratio
0.47
P/E Growth
N/A
Net Income
£-5,070,000.00
Net Margins
N/A
Pretax Margin
N/A
Return on Equity
-106.77%
Return on Assets
-37.91%

Debt

Debt-to-Equity Ratio
14.25
Current Ratio
1.51
Quick Ratio
2.02

Sales & Book Value

Annual Sales
£783,000.00
Price / Sales
2.46
Cash Flow
GBX 5.55 per share
Price / Cash Flow
0.61
Book Value
GBX 4 per share
Price / Book
0.84

Miscellaneous

Outstanding Shares
57,170,000
Free Float
N/A
Market Cap
£1.93 million
Optionable
Not Optionable
Beta
0.69
12 Stocks Corporate Insiders are Abandoning Cover
12 Stocks Corporate Insiders are Abandoning

If a company's CEO, COO, and CFO were all selling shares of their stock, would you want to know?

Get This Free Report

Key Executives

  • Mr. Iain Gladstone Ross B.Sc. (Age 70)
    BSc (Hons), C.DIR, CH.D, Executive Chairman
    Comp: $430k
  • Mr. John Michael Hawkins A.C.A. (Age 58)
    Company Secretary, CFO & Director
    Comp: $192.91k
  • Dr. John David Sinden B.A. (Age 73)
    BA, M.A., MA, Ph.D., Co-Founder
    Comp: $103k
  • Ms. Suzanne Hancock
    Chief Operations Officer
  • Dr. Randolph Corteling Ph.D.
    Chief Scientific Officer
  • Mr. Simon Dew
    Chief Business Officer

Key Competitors

View All Competitors

Insiders

View All Insider Transactions

RENE Stock Analysis - Frequently Asked Questions

How have RENE shares performed in 2024?

ReNeuron Group's stock was trading at GBX 3.50 at the beginning of the year. Since then, RENE stock has decreased by 3.6% and is now trading at GBX 3.38.
View the best growth stocks for 2024 here.

How were ReNeuron Group's earnings last quarter?

ReNeuron Group plc (LON:RENE) issued its quarterly earnings data on Monday, July, 20th. The company reported ($35.90) earnings per share for the quarter, topping the consensus estimate of ($50.20) by $14.30.

What other stocks do shareholders of ReNeuron Group own?

Based on aggregate information from My MarketBeat watchlists, some companies that other ReNeuron Group investors own include 10094 (IRD.TO) (IRD), Sareum (SAR), ValiRx (VAL), IOG (IOG), Dignity (DTY), Tri-Star Resources plc (TSTR.L) (TSTR), Sirius Minerals (SXX), Collagen Solutions plc (COS.L) (COS), RenovaCare (RCAR) and ReNeuron Group (RNUGF).

How do I buy shares of ReNeuron Group?

Shares of RENE stock and other U.K. stocks can be purchased through online brokerage accounts that support trading on the London Stock Exchange (LSX). Some U.K. companies can be purchased through major U.S. brokerages in the form of American Depository Receipts (ADRs), which are placeholder equities held in a trust by a bank that represent shares of a foreign stock.
Compare Top Brokerages Here.

This page (LON:RENE) was last updated on 4/19/2024 by MarketBeat.com Staff

From Our Partners
Healthcare Takes A Big Step Forward With The Help Of AI
The Bull Report
The Best AI Stock to Own in the World Today is Trading for Just $25
Banyan Hill Publishing
The “Perfect Storm” for Gold
Gold Safe Exchange
Biden’s $374B Giveaway Into This Sector
DTI
Your Money is Not Safe
American Alternative
The #1 Crypto for 2024
InvestorPlace
He Is Giving Away Bitcoin
Crypto Swap Profits
The "Smart Money" Is Ready for May 1st Are You?
Stansberry Research